RETRACTED: Protective effect of roscovitine against rotenone-induced parkinsonism

Chen, Yan; Hou, Yiwei; Ge, Ruli; Han, Jianing; Xu, Jing; Chen, Jinbo; Wang, Hongcai

doi:10.3233/rnn-180817

Cited by 7 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…as well as intranasal and dermal exposure to the drug, with a number of different readouts to assess histologic, biochemical, and in vivo correlates of human Parkinson’s disease [ 21 , 22 , 38 , 39 , 40 , 41 , 42 ]. Comparisons of the results of these studies reveal high within- and between-study variability even with very similar protocols, but particularly high-dose oral rotenone looked promising and has been used as a PD model in multiple studies exploring drug, diet, stress, or LRRK2 effects in mice [ 23 , 25 , 26 , 27 , 28 , 29 , 30 , 36 , 39 , 43 , 44 , 45 ]. Interestingly, studies addressing drug or diet effects found quite stable reductions in RotaRod running of about 50% and restoration with the candidate drug [ 23 , 25 , 26 , 27 , 28 , 29 , 30 ], whereas studies addressing add-on effects of stress or LRRK2 mutation found minor or no effect of rotenone alone but a serious drop in combination [ 36 , 39 , 45 ], suggesting aim-dependent biases.…”

Section: Discussionmentioning

confidence: 99%

“…Nevertheless, the majority of oral rotenone-PD studies claimed the model as suitable [ 21 , 23 , 25 , 26 , 27 , 28 , 29 , 30 , 33 , 34 , 35 , 37 , 43 , 44 , 58 , 59 ]. Some of these studies used different solvents, such as sunflower oil 4% or 2% carboxymethylcellulose with 1.25% chloroform, which likely affects absorption [ 59 , 60 , 61 , 62 ] but not so much first-pass metabolism.…”

Section: Discussionmentioning

confidence: 99%

“…To reduce animal suffering and mortality, alternative methods of administration including oral, subcutaneous, and intraperitoneal have been investigated and were described as being reproducible and reliable [ 18 , 19 , 20 , 21 , 22 ]. Oral administration has also been established in mice [ 21 , 22 ] and was used as a model in multiple experimental studies investigating novel therapeutic compounds against PD [ 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 ]. Therefore, we adopted the described high-dose treatment regimen of oral rotenone in mice exactly following the published protocol, with RotaRod running as the behavioral and tyrosine hydroxylase immunostaining as the biological readouts [ 21 , 22 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Non-Reproducibility of Oral Rotenone as a Model for Parkinson’s Disease in Mice

Niederberger

Wilken-Schmitz

Manderscheid

et al. 2022

IJMS

View full text Add to dashboard Cite

Oral rotenone has been proposed as a model for Parkinson’s disease (PD) in mice. To establish the model in our lab and study complex behavior we followed a published treatment regimen. C57BL/6 mice received 30 mg/kg body weight of rotenone once daily via oral administration for 4 and 8 weeks. Motor functions were assessed by RotaRod running. Immunofluorescence studies were used to analyze the morphology of dopaminergic neurons, the expression of alpha-Synuclein (α-Syn), and inflammatory gliosis or infiltration in the substantia nigra. Rotenone-treated mice did not gain body weight during treatment compared with about 4 g in vehicle-treated mice, which was however the only robust manifestation of drug treatment and suggested local gut damage. Rotenone-treated mice had no deficits in motor behavior, no loss or sign of degeneration of dopaminergic neurons, no α-Syn accumulation, and only mild microgliosis, the latter likely an indirect remote effect of rotenone-evoked gut dysbiosis. Searching for explanations for the model failure, we analyzed rotenone plasma concentrations via LC-MS/MS 2 h after administration of the last dose to assess bioavailability. Rotenone was not detectable in plasma at a lower limit of quantification of 2 ng/mL (5 nM), showing that oral rotenone had insufficient bioavailability to achieve sustained systemic drug levels in mice. Hence, oral rotenone caused local gastrointestinal toxicity evident as lack of weight gain but failed to evoke behavioral or biological correlates of PD within 8 weeks.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Non-Reproducibility of Oral Rotenone as a Model for Parkinson’s Disease in Mice

Niederberger

Wilken-Schmitz

Manderscheid

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…The vulnerability of the midbrain to rotenoneinduced oxidative stress could also be seen from other works. 9,10 Embelin, (2,5-dihydroxy-3-undecyl-1,4-benzoquinone) is an active constituent of the fruits of Embelia ribes Burm (Family: Myrsinaceae). Several works on embelin suggest many pharmacological actions rendered by this compound such as antioxidant, 11 antidiabetic, 12 antifertility, 13 anti-bacterial, 14 antitumor, analgesic and antiinflammatory.…”

Section: Introductionmentioning

confidence: 99%

Embelin and Levodopa Combination Therapy Mitigates Parkinson's Disease Complications in Mice

Koppal¹,

Ramachandra²,

Sukumar³

et al. 2021

IJPER

View full text Add to dashboard Cite

Purpose: The present work evaluated the neuroprotective potential of embelin either alone and in combination with Levodopa in rotenone induced PD (Parkinson's disease) model mice. Methods: Swiss albino male adult mice were randomly divided into 7 groups. Group-1 (Control) received 2mL/kg olive oil by oral route (p.o.), Groups from 2 to 7 were induced with 2.5mg/kg rotenone by intraperitoneal route (i.p.), levodopa was administered to Group-3. Group-4 and Group-5 were given 20mg/kg and 40mg/ kg embelin p.o. Group 6 and 7 were given embelin p.o. at dose of 20 mg and 40 mg/ kg respectively and also 7.5 mg/kg Levodopa p.o. At the end of the experiment (22 nd day), blood was withdrawn by retro-orbital puncture to estimate various biochemical parameters and organs such as liver and brain, were dissected for histopathological and histochemical studies. Results: Drug treatment with a combination of embelin (40 mg/ kg) and levodopa (7.5 mg/kg) to PD mice showed better neuroprotective activity than the remaining drug treatment groups based on the results from biochemical, histopathology and α-synuclein protein immunohistochemistry. Conclusion: The current in-vivo research showed that mice treated with embelin at a dose of 40 mg/kg b.w. along with reduced levodopa (7.5 mg/kg) standard therapy was effective to ameliorate rotenone induced PD complications.

show abstract

Intragastric Administration of Casein Leads to Nigrostriatal Disease Progressed Accompanied with Persistent Nigrostriatal—Intestinal Inflammation Activited and Intestinal Microbiota—Metabolic Disorders Induced in MPTP Mouse Model of Parkinson’s Disease

Liu

Tang

et al. 2021

Neurochem Res

View full text Add to dashboard Cite

RETRACTED: Protective effect of roscovitine against rotenone-induced parkinsonism

Abstract: Mouse models of Parkinson's disease were established by oral rotenone administration and reproduced some of the features of dopaminergic neuronal degeneration. Roscovitine protects against rotenone-induced parkinsonism.

Cited by 7 publications

References 24 publications

Non-Reproducibility of Oral Rotenone as a Model for Parkinson’s Disease in Mice

Non-Reproducibility of Oral Rotenone as a Model for Parkinson’s Disease in Mice

Embelin and Levodopa Combination Therapy Mitigates Parkinson's Disease Complications in Mice

Intragastric Administration of Casein Leads to Nigrostriatal Disease Progressed Accompanied with Persistent Nigrostriatal—Intestinal Inflammation Activited and Intestinal Microbiota—Metabolic Disorders Induced in MPTP Mouse Model of Parkinson’s Disease

Contact Info

Product

Resources

About